Client programs using CHOMax follow platform-defined workflows and phase-appropriate practices across the development lifecycle.

Aragen's new cell line development and early manufacturing platform, CHOMax, can cut timelines to approximately 10 months.

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

Plant regeneration relies on a delicate balance between stem cell renewal and differentiation, yet the evolutionary origin ...

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

SHENZHEN, GUANGDONG, CHINA, January 7, 2026 /EINPresswire.com/ -- A Significant Achievement in Quality Management ...

H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim ...

Crops increasingly need to thrive in a broader range of conditions, including drought, salinity, and heat. Traditional plant ...

Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop ...

Diliman have synthesized a new class of hybrid molecules that may help limit the spread of cancer cells by targeting a key enzyme involved in tumor progression. The compounds, developed by Christian ...

Bruce Ogilvie, Executive Chairman of Alliance Entertainment, appears on the RedChip Small Stocks Big Money ™ show on Bloomberg TV to discuss Alliance Entertainment’s position at the center of the ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 ...